Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
ConclusionsThe triplet combination of erlotinib, cetuximab, and bevacizumab was well tolerated, conferring clinical benefit in heavily pretreated patients. Future studies are warranted with second or third-generation EGFR tyrosine kinase triplet combinations in the EGFR pathway aberrant patients.Trial Registration: ClinicalTrials.gov Identifier: NCT00543504. Sponsor(s): National Cancer Institute (NCI), MD Anderson Cancer Center
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
More News: Avastin | Bleeding | Cancer | Cancer & Oncology | Cervical Cancer | Colorectal Cancer | Erbitux | Head and Neck Cancer | Hematology | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma | Study | Tarceva | Thyroid | Thyroid Cancer | Toxicology